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Abstract
This is the first evaluation study on the
acceptability and accuracy of the Reflotron, a desk-
top analyzer for cholesterol screening in general
practice in Hong Kong. Patients aged 21-60
attending a Government general outpatient clinic in
Hong Kong were randomly selected. The acceptance
rate of screening was 69%. A total of 1113 subjects
had their cholesterol levels screened by the Reflotron.
The accuracy of the Reflotron was assessed by
comparing its results to laboratory blood cholesterol
(BC) results in 125 subjects. The mean error of the
Reflotron cholesterol measurements was 6% which
was larger than that recommended by the American
National Cholesterol Education Programme.
Therefore, the diagnosis or treatment of hypercho-
lesterolaemia should not be based on the Reflotron
result alone. There was a good linear correlation
between the Reflotron cholesterol (RC) and blood
cholesterol (BC) with a negative bias in the
Reflotron results. Blood cholesterol could be
predicted from RC by the regression equation: BC =
0.8395 + 0.8995 x RC. The Reflotron is useful as
an initial screening test for hypercholesterolaemia in
the low risk population. The threshold levels need to
be adjusted accordingly, and abnormal results
should be confirmed by standard laboratory tests. It
is estimated that one could save H.K.$51.6 million
if the Reflotron instead of the laboratory were used
to screen all people aged 40 to 60 years old in Hong
Kong once.
Keywords: Hypercholesterolaemia,
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Introduction
Hypercholesterolaemia is one of the most
important risk factors of coronary heart disease
(CHD).1'6 The WHO Expert Committee on
prevention of coronary heart disease
recommended that identifying and helping
individuals at special risk is an important
preventive strategy.7 The detection of
hypercholesterolaemia is important for the overall
evaluation and reduction of the CHD risk of an
individual.
An earlier study found that only 30% of the
Chinese in Hong Kong accepted blood tests for
cholesterol screening.8 Many refused because they
were afraid of venepuncture and some found it
too inconvenient to return on another day for a
blood test. The use of a desk-top dry chemistry
analyzer may improve the acceptability of
screening by saving a venepuncture and an extra
visit.9-11
^Address for correspondence: Dr. Cindy L.K. Lam, General Practice Unit, 3rd floor, Ap Lei Chau Clinic, 161 Main Street, Ap Lei Chau,
Hong Kong.
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The Reflotron is the most popular desk-top
analyzer among general practitioners in Europe.12
It measures cholesterol with a drop of capillary
blood obtained by finger-prick and the result is
known within a few minutes. Many general
practitioners in Hong Kong also use the
Reflotron in their offices but there is no
published data on its acceptability and accuracy
locally.
This is the first evaluation study on the
acceptability and accuracy of the Reflotron for
opportunistic cholesterol screening on Chinese
patients in general practice in Hong Kong. All
the published data on the Reflotron was obtained
from Western populations, and some had
contradictory conclusions.11'13'16
Method
The study was carried out between June 15
and September 15, 1990 at a four-doctor
Government general outpatient clinic in Hong
Kong. Two trained interviewers sampled the
subjects from patients attending two of the four
doctors. The doctors were selected in rotation
during the study period so that their patients had
equal chance to be sampled.
One in every four patients consulting the
selected doctors were approached by the
interviewers in the waiting hall before their
consultations. Chinese patients aged 21 to 60
years old were invited to take part in the study.
The next patient was invited if the original
subject was outside the age range, was not
Chinese, was sampled before, or refused to
participate. Each participant was interviewed
with a structured questionnaire on personal
demography and CHD risk factors. Each subject
was then seen by the second author (M.G.C.)
who measured his/her weight, height, blood
pressure, and serum cholesterol. Serum blood
cholesterol was measured by the Reflotron desk-
top analyzer (Boehringer Mannheim, W.
Germany, 1988) on a drop of capillary blood
obtained by a finger prick. All the tests were
performed by the second author (M.G.C.) who
received a training session from the supplier
before the study. The test procedures listed in
the operation manual were closely followed. The
machine was calibrated with the check strips
from the supplier before the screening tests each
day. Quality checks using standard sera from the
supplier were performed once a week.
All patients with total cholesterol levels >
6.2mmol/l, and those with levels > 5.2mmol/l and
two additional CHD risk factors were invited to
have further blood tests for cholesterol and
lipoprotein analysis. The CHD risk factors
included male sex, family history of premature
(before the age of 55) coronary heart death or
sudden death, current smoking of 5: 10 cigarettes
per day, hypertension on treatment or a blood
pressure measurement > 160/90, diabetes mellitus,
history of definite stroke or occlusive peripheral
vascular disease, and BMI > 30.17
Subjects who required further blood tests
were asked to return within three days of the
initial screening following a 12 hours fast. Their
venous blood samples were sent to the Sai Ying
Pun Government Biochemistry Laboratory for the
assay of total cholesterol (TC), triglyceride (TG)
and high density lipoprotein (HDL) by the
Beckman Synchron CX5 analyzer. The
Laboratory carries out quality checks twice a
month by an international quality control
programme, the NUREX Diagnostic Clinical
Chemistry Quality Assessment Programme.
The low density lipoprotein (LDL) level was
calculated by the Friedewald formula: LDL = TC
- HDL - (TG / 2.2) mmol/l.u Those found to
have elevated LDL according to their relative
CHD risks were called back for further assessment
and management.
All the data were analyzed using the SPSS-
PC+ (Statistical Packages for Social Science —
Personal Computer) programme.19
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Results
Sample
There were 1616 (56% females and 44%
males) eligible patients approached, 1113 (69%)
completed the questionnaire and Reflotron
cholesterol screening. These 1113 subjects made
up the total sample for further analysis. There
were 622 (56%) females and 491 (44%) males.
The sex ratio of the screened sample was the same
as that of the initial eligible population. The
mean age of the sample was 38.7 years (S.D.
11.2). The distribution of the social class by
occupation20 and the CHD risk factors of the
sample is shown in Table 1. Twenty-one percent
of them had two or more CHD risk factors. Nine
percent had previously had their blood cholesterol
checked.
Table 1: Distribution of the Social Class and
Coronary Heart Disease (CHD) Risk
Factors
Proportion of Sample ( N=1113)
Social Class
I
II
III
IV
V
CHD Risk Factors
Current Smoker
Ex-smoker
CHD
Family History of CHD
Hypertension
BMI 2: 30
Diabetes Mellitus
Hyperlipidaemia
Stroke
Other atherosclerosis
11%
61%
17%
10%
3%
1%
5%
14%
5%
4%
2%
1%
0.4%
A total of 143 (13%) subjects required further
cholesterol and lipoprotein tests according to our
study criteria. Sixty-nine (6%) individuals had RC
> 6.2mmolll and 74 (7%) had RC 5.2 to
6.2mmol/l and two additional CHD risk factors.
One hundred and twenty-five (87%) of them
returned for the blood tests.
Accuracy of Cholesterol Tests by the Reflotron
The accuracy of the cholesterol measurements
by the Reflotron was assessed by comparing the
Reflotron and blood test results of 125 subjects
who had both tests. The blood test results by the
laboratory were used as the gold standard.
Correlation analysis showed that there was a
strong positive correlation between the two results
with a correlation coefficient of 0.805 (p <
0.0001). Figure 1 shows the correlation plot of
blood cholesterol (BC) by Reflotron cholesterol
(RC) of the 125 subjects. The BC value could be
calculated from the RC by the regression equation
: BC = 0.8395 + 0.8995 x RC. The three
threshold levels of RC that corresponded to the
three commonly used thresholds of hypercho-
lesterolaemia of 5.2, 6.2 and 7.8mmo///19'21 were
4.8, 6.0 and 7.7/nmo///, respectively.
Figure 1: Correlation Plot between Reflotron
Cholesterol and Blood Cholesterol
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The mean cholesterol level of the 125 subjects
was 6.4 (S.D. 0.86, range 5.2 - 10.8) mmol/l by
Reflotron and 6.6 (S.D. 0.96, range 4-10.7) mmol/l
by blood test. The difference between the means
was 3%. The difference between each paired
results ranged from O to 35%. Five subjects had
differences of more than 20%. If these five
subjects were excluded from the analysis, the
mean error was 6% (S.D. 0.045, range O - 18%).
If they were included, the mean error became 7%
(S.D. 0.057). The classification of individuals by
cholesterol levels either the Reflotron, or blood
tests are compared in Table 2. Table 3 shows the
sensitivities, specificities, and the predictive values
of the Reflotron in detecting blood cholesterol
levels of > 6.2mmol/l by using a RC threshold of
6.0mmol/l or 6.2mmol/l.
Table 2: Accuracy of Cholesterol Measurement
by the Reflotron
Laboratory Cholesterol
> 6.2 mmol/l S 6.2 mmol/l
(N=83) (N=42)
Reflotron Cholesterol
> 6.2 mmol/l 59
(N=70)
S 6.2 mmol/l 24
(N=55)
> 6.0 mmol/l 68
(N=81)
s 6.0 mmol/l 15
<N=44)
11
31
13
29
Table 3: The Sensitivity, Specificity, Predictive
Values of the Reflotron for blood
cholesterol > 6.2mmol/l
Reflotron Threshold Level
>6.0 mmol/l >6.2 mmol/l
Sensitivity 82% 71%
Specificity 69% 74%
Positive prediction
Negative prediction 66% 56%
Discussion
The Reflotron cannot replace standard
laboratory tests for the diagnosis of, or monitoring
the treatment of, hypercholesterolaemia. The
mean error of Reflotron measurements in our
study was greater than the 5% recommended by
the expert panel of the American National
Cholesterol Education Programme (NCEP). The
NCEP actually recommended that the error
should ideally be no greater than 3%.21
We found a negative bias in the Reflotron
measurements as reported by Koch et al,ls but
different studies have reported different
results.11-13'16 The accuracy of most desk-top
analyzers has not been fully established. The
error and bias of different desk-top analyzers,
even of the same model and brand, may be
different. The possible causes of error are
multiple: calibration, assay technique, reagent strip
characteristics, and possible difference between
cholesterol concentration in capillary and venous
blood samples.14'15 Therefore, it is essential to
check the accuracy of and calibrate a desk-top
analyzer against standard laboratory results before
it is used clinically. Regular quality checks should
also be done to assure the accuracy of the test
results.
The Reflotron results had good linear
correlation with laboratory results but the values
needed to be adjusted according to the regression
equation. According to our results, a RC
threshold levels of 4.8mmol/l and 6mmol/l should
be used to identify those with blood cholesterol
levels of >5.2mmol/l and > 6.2mmol/l respectively.
Using a RC threshold of d.Ommolll, the Reflotron
had a sensitivity of 82% and specificity of 69% in
detecting persons with blood cholesterol of
>6.2mmol/l.
The negative predictive value in our
validation sample was relatively low (66%)
because a high proportion (66%) of subjects had
cholesterol > f>.2mmolll. If this were applied to
260
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the total sample of which 96 (9%) persons had
RC > 6.0mmo/// (corresponds to blood cholesterol
> 6.2mmol/l), then the negative predictive value
would be 97%. This means that the Reflotron is
useful as an initial screening test to exclude
hypercholesterolaemia in a low-risk population. It
can save a lot of unnecessary blood tests because
only one in six persons requires further tests.
The biggest advantage of the Reflotron is its
high acceptability which is essential for a screening
test to be useful.22 The acceptance rate was
improved from 30% by blood test8 to 69%.
People were also much more motivated to return
for further blood tests when the initial abnormal
cholesterol results were fed back to them.
The Reflotron is cheaper than blood test for
initial screening for possible cases of hypercho-
lesterolaemia. Excluding the capital cost of the
machine each Reflotron cholesterol reagent strip
costs about H.K.S17 (1994 price quoted by
supplier). A cholesterol test done by a private
laboratory in Hong Kong costs about H.K.$60.23
If the 1.2 million people aged 40 to 60 years old
in Hong Kong were to be screened once,24 it could
save 51.6 million HK$(1.2 million X ($60 - $17)).
Conclusion
The Reflotron cannot replace laboratory tests
for the diagnosis or monitoring the treatment of
hypercholesterolaemia because the mean error in
measurement was as big as 6%. The main use of
the Reflotron is for initial case finding, it is well
accepted by patients and can save a lot of
unnecessary blood tests. It is more cost-effective
than standard laboratory test for initial cholesterol
screening in a population with relatively low
prevalence of hypercholesterolaemia like ours.
It must be stressed that any abnormal
Reflotron cholesterol result must be confirmed by
standard laboratory blood tests before the
diagnosis of hypercholesterolaemia is made. The
LDL and HDL levels should also be measured in
these individuals so that treatment can be guided
by the LDL and HDL levels.25 Otherwise, the
assay error may cost much more in terms of
patient anxiety and unnecessary treatment than
the saving from the screening tests.
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